On September 15, Thermo Fisher Scientific rose 3.08% in regular trading, trading around $630.43 per share, with turnover of approximately $90.86 million.

On the news front, a cluster of investment bank upgrades has fueled bullish sentiment around the stock. UBS notably upgraded Thermo Fisher to Buy from Neutral with a target price of $730, up sharply from $540. Baird raised its target to $686 from $652 while maintaining an Outperform rating, and HSBC lifted its target to $690 from $660. Additionally, institutional research firm Citrini included Thermo Fisher in its healthcare picks-and-shovels portfolio, citing accelerating AI adoption in drug development and a recovery in biotech funding as sustained tailwinds for life sciences tools providers.

Separately, Mayo Clinic and Thermo Fisher announced the co-founding of Precure, a new company aimed at detecting disease signals before symptoms appear, combining Mayo's clinical expertise with Thermo Fisher's commercialization capabilities. The company also recently reported strong Q2 results, with adjusted EPS of $6.03 beating estimates of $5.71 and revenue of $11.99 billion exceeding the $11.71 billion consensus, providing a solid fundamental backdrop.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)